SOURCE: Barrier Therapeutics, Inc.

July 21, 2005 12:45 ET

Barrier Therapeutics to Present at Banc of America Securities Specialty Pharmaceuticals Conference

PRINCETON, NJ -- (MARKET WIRE) -- July 21, 2005 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Anne M. VanLent, Executive Vice President, Chief Financial Officer and Treasurer of Barrier Therapeutics, is scheduled to provide an update on the Company and participate in a moderated discussion with other industry members at the Banc of America Securities 2005 Specialty Pharmaceuticals Conference: "New Products, New Paradigms in Health Care." The conference is being held from July 27-29, 2005 in Southampton, NY. Ms. VanLent is scheduled to present on Thursday, July 28th at 8:45 am Eastern Time.

Ms. VanLent's presentation will also be available live via a webcast that can be accessed through the Company's website:

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. The Company currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the U.S. and Canada for the treatment of solar lentigines, a common condition also known as "age spots," and recently obtained the Canadian distribution rights for Vaniqa® (eflornithine hydrochloride) Cream 13.9% for slowing the growth of unwanted facial hair in women. Barrier has eight product candidates in various stages of clinical development. The four most advanced product candidates include one for the treatment of diaper dermatitis complicated by candidiasis, which is under FDA review, and three products, which are in or entering Phase 3 clinical trials for the treatment of seborrheic dermatitis, onychomycosis, and congenital ichthyosis. Barrier has product candidates in earlier stages of clinical development for the treatment of acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium, and Ontario, Canada.

Web site:

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent

    Noonan Russo
    Emily Poe